# Prognosis and Dissection of Immunosuppressive Microenvironment in Breast Cancer Based on Fatty Acid Metabolism-Related Signature

**Authors:** Yuhui Tang, Wenwen Tian, Jindong Xie, Yutian Zou, Zehao Wang, Ning Li, Yan Zeng, Linyu Wu, Yue Zhang, Song Wu, Xiaoming Xie, Lu Yang

PMC · DOI: 10.3389/fimmu.2022.843515 · Frontiers in Immunology · 2022-03-31

## TL;DR

This study explores how fatty acid metabolism affects breast cancer prognosis and the tumor's immune environment, offering new insights for better treatment strategies.

## Contribution

A novel fatty acid metabolism-related gene signature is developed to predict breast cancer prognosis and immune microenvironment features.

## Key findings

- A 6-gene fatty acid metabolism signature was developed and validated for breast cancer prognosis.
- The signature correlates with clinical parameters like T, N stages and PAM50 subtypes.
- The study reveals connections between fatty acid metabolism and immune checkpoint inhibitors, tumor immunity, and therapy resistance.

## Abstract

Fatty acid metabolism has been deciphered to augment tumorigenesis and disease progression in addition to therapy resistance via strengthened lipid synthesis, storage, and catabolism. Breast cancer is strongly associated with the biological function of fatty acid metabolism owing to the abundant presence of adipocytes in breast tissue. It has been unraveled that tumor cells exhibit considerable plasticity based on fatty acid metabolism, responding to extra-tumoral and a range of metabolic signals, in which tumor microenvironment plays a pivotal role. However, the prognostic significance of fatty acid metabolism in breast cancer remains to be further investigated. Alongside these insights, we retrieved 269 reliable fatty acid metabolism-related genes (FMGs) and identified the landscape of copy number variations and expression level among those genes. Additionally, 11 overall survival-related FMGs were clarified by univariate Cox hazards regression analysis in The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases. Subsequently, a prognostic signature based on 6 overall survival (OS)-related FMGs was generated using Lasso Cox hazards regression analysis in TCGA dataset and was validated in two external cohorts. The correlation between the signature and several essential clinical parameters, including T, N, and PAM50 subtypes, was unveiled by comparing the accumulating signature value in various degrees. Furthermore, an optimal nomogram incorporating the signature, age, and American Joint Committee on Cancer (AJCC) stage was constructed, and the discrimination was verified by C-index, the calibration curve, and the decision curve analysis. The underlying implications for immune checkpoints inhibitors, the landscape of tumor immune microenvironment, and the predictive significance in therapy resistance to diverse strategies were depicted ultimately. In conclusion, our findings indicate the potential prognostic connotation of fatty acid metabolism in breast cancer, supporting novel insights into breast cancer patients’ prognosis and administrating effective immunotherapy.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** HMGCS1 (3-hydroxy-3-methylglutaryl-CoA synthase 1) [NCBI Gene 3157] {aka CMYO28, HMGCS}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, RDH16 (retinol dehydrogenase 16) [NCBI Gene 8608] {aka RODH-4, RODH4, SDR9C8, hRDH-E}, SDHA (succinate dehydrogenase complex flavoprotein subunit A) [NCBI Gene 6389] {aka CMD1GG, FP, MC2DN1, NDAXOA, PGL5, PPGL5}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, IDO1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 3620] {aka IDO, IDO-1, INDO}, BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, LTA4H (leukotriene A4 hydrolase) [NCBI Gene 4048], ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, RPTOR (regulatory associated protein of MTOR complex 1) [NCBI Gene 57521] {aka KOG1, Mip1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SLC27A1 (solute carrier family 27 member 1) [NCBI Gene 376497] {aka ACSVL5, FATP, FATP-1, FATP1}, CEL (carboxyl ester lipase) [NCBI Gene 1056] {aka BAL, BSDL, BSSL, CELL, CEase, FAP}, ELOVL1 (ELOVL fatty acid elongase 1) [NCBI Gene 64834] {aka CGI-88, IKSHD, Ssc1}, CYP4F11 (cytochrome P450 family 4 subfamily F member 11) [NCBI Gene 57834] {aka CYPIVF11}, GSTZ1 (glutathione S-transferase zeta 1) [NCBI Gene 2954] {aka GSTZ1-1, MAAI, MAAID, MAI}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PVR (PVR cell adhesion molecule) [NCBI Gene 5817] {aka CD155, HVED, NECL5, Necl-5, PVS, TAGE4}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 397286], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SREBF1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 6720] {aka HMD, IFAP2, SREBP1, bHLHd1}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], SCD (stearoyl-CoA desaturase) [NCBI Gene 6319] {aka FADS5, MSTP008, SCD1, SCDOS, hSCD1}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, CPT1A (carnitine palmitoyltransferase 1A) [NCBI Gene 1374] {aka CPT I, CPT1, CPT1-L, CPTI-L, L-CPT1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD96 (CD96 molecule) [NCBI Gene 10225] {aka TACTILE}, ACLY (ATP citrate lyase) [NCBI Gene 47] {aka ACL, ATPCL, CLATP}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FAP (fibroblast activation protein alpha) [NCBI Gene 2191] {aka DPPIV, FAPA, FAPalpha, SIMP}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, HCCS (holocytochrome c synthase) [NCBI Gene 3052] {aka CCHL, LSDMCA1, MCOPS7, MLS}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, ATP8B1 (ATPase phospholipid transporting 8B1) [NCBI Gene 5205] {aka ATPIC, BRIC, FIC1, ICP1, PFIC, PFIC1}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, S1PR4 (sphingosine-1-phosphate receptor 4) [NCBI Gene 8698] {aka EDG6, LPC1, S1P4, SLP4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}
- **Diseases:** OS (MESH:D011475), American (MESH:D006478), mycoplasma infection (MESH:D009175), metastasis (MESH:D009362), inflammatory (MESH:D007249), NPG (MESH:D009303), colorectal cancer (MESH:D015179), breast (MESH:D061325), BC (MESH:D001943), liver cancer (MESH:D006528), Cancer (MESH:D009369), FMGs (MESH:D008659), lung cancer (MESH:D008175)
- **Chemicals:** cholesterol (MESH:D002784), sphingomyelin (MESH:D013109), lipid (MESH:D008055), rapamycin (MESH:D020123), AZD8186 (MESH:C000595972), SYBR Green (MESH:C098022), CO2 (MESH:D002245), glycosphingolipid (MESH:D006028), dichloroacetate (MESH:D003999), phospholipids (MESH:D010743), FA (MESH:D005227), FFAs (MESH:D005230), triglyceride (MESH:D014280), FMI (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MCF10A. — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), SK-BR-3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), BT549 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_1092), T47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), LM22 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_A1IU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9009264/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9009264/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC9009264/full.md

---
Source: https://tomesphere.com/paper/PMC9009264